TFF Pharmaceuticals Q1 2024 GAAP EPS $(2.40) Misses $(2.26) Estimate, Sales $203.27K Beat $75.00K Estimate
TFF Pharmaceuticals Q1 2024 GAAP EPS $(2.40) Misses $(2.26) Estimate, Sales $203.27K Beat $75.00K Estimate
TFF Pharmicals 2024年第一季度GAAP每股收益（2.40）未达到预期（2.26）美元，销售额20.327万美元超过7.5万美元的预期
TFF Pharmaceuticals (NASDAQ:TFFP) reported quarterly losses of $(2.40) per share which missed the analyst consensus estimate of $(2.26) by 6.19 percent. The company reported quarterly sales of $203.27 thousand which beat the analyst consensus estimate of $75.00 thousand by 171.03 percent. This is a 295.25 percent increase over sales of $51.43 thousand the same period last year.
TFF Pharmicals（纳斯达克股票代码：TFFP）公布的季度亏损为每股2.40美元，比分析师普遍预期的2.26美元（2.26美元）低6.19％。该公司公布的季度销售额为203,270美元，比分析师普遍预期的7.5万美元高出171.03％。这比去年同期的51,430美元的销售额增长了295.25％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。